Patents Assigned to Inex Pharmaceuticals Corporation
-
Publication number: 20090041834Abstract: This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.Type: ApplicationFiled: March 7, 2008Publication date: February 12, 2009Applicants: Inex Pharmaceuticals Corporation, Board of Regents, The University of Texas SystemInventors: Andreas SARRIS, Fermando CABANILLAS, Patricia M. LOGAN, Clive T.R. BURGE, James H. GOLDIE, Murray S. WEBB
-
Publication number: 20090028933Abstract: The present invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of leukemias, including acute lymphoblastic leukemia (ALL). These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, in combination with dexamethasone to a mammal with a leukemia.Type: ApplicationFiled: February 11, 2008Publication date: January 29, 2009Applicant: Inex Pharmaceuticals CorporationInventor: Deborah A. Thomas
-
Publication number: 20070172950Abstract: Novel lipid-nucleic acid particulate complexes which are useful for in vitro or in vivo gene transfer are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. Upon removal of a solubilizing component (i.e., detergent or an organic solvent) the lipid-nucleic acid complexes form particles wherein the nucleic acid is serum-stable and is protected from degradation. The particles thus formed have access to extravascular sites and target cell populations and are suitable for the therapeutic delivery of nucleic acids.Type: ApplicationFiled: March 23, 2007Publication date: July 26, 2007Applicants: The University of British Columbia, INEX Pharmaceuticals CorporationInventors: Jeffrey Wheeler, Marcel Bally, Yuan-Peng Zhang, Dorothy Reimer, Michael Hope, Pieter Cullis, Peter Scherrer
-
Patent number: 7247316Abstract: This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.Type: GrantFiled: February 18, 2004Date of Patent: July 24, 2007Assignees: Board of Regents, The University of Texas System, Inex Pharmaceuticals CorporationInventors: Andreas H Sarris, Fernando Cabanillas, Patricia M Logan, Clive T R Burge, James H Goldie, Murray S Webb
-
Patent number: 7244450Abstract: This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.Type: GrantFiled: December 4, 2003Date of Patent: July 17, 2007Assignees: Inex Pharmaceuticals Corporation, Board of Regents, The University of Texas SystemInventors: Andreas H. Sarris, Fernando Cabanillas, Patricia M. Logan, Clive T. R. Burge, James H. Goldie, Murray S. Webb
-
Publication number: 20060269594Abstract: This invention relates to liposomal antineoplastic agents (e.g., camptothecin) compositions and methods of using such compositions for treating neoplasia and for inhibiting angiogenesis. The compositions and methods are useful for modulating the plasma circulation half-life of an active agent.Type: ApplicationFiled: May 8, 2006Publication date: November 30, 2006Applicant: Inex Pharmaceuticals CorporationInventors: Thomas Madden, Sean Semple, Quet Ahkong
-
Patent number: 7060828Abstract: This invention relates to improved liposomal camptothecin compositions and methods of manufacturing and using such compositions for treating neoplasia and for inhibiting angiogenesis.Type: GrantFiled: June 29, 2001Date of Patent: June 13, 2006Assignee: Inex Pharmaceuticals CorporationInventors: Thomas D. Madden, Sean C. Semple
-
Publication number: 20060093662Abstract: This invention relates to improved liposomal camptothecin compositions and methods of manufacturing and using such compositions for treating neoplasia and for inhibiting angiogenesis.Type: ApplicationFiled: December 6, 2005Publication date: May 4, 2006Applicant: Inex Pharmaceuticals CorporationInventors: Thomas Madden, Sean Semple
-
Patent number: 6986902Abstract: The present invention relates generally to the amphiphilic polyelectrolyte, poly(2-ethylacrylic acid) and covalently bonded lipids to generate Lipo-PEAA. These Lipo-PEAA are then used to make pH-sensitive liposomes which become unstable, permeable or fusogenic with certain pH changes. In addition, this invention generally describes methods for delivering therapeutic compounds and drugs to target cells by administering to a host the pH-sensitive liposomes of the present invention.Type: GrantFiled: April 27, 1999Date of Patent: January 17, 2006Assignee: Inex Pharmaceuticals CorporationInventors: Tao Chen, Yuehua He, Peter Cullis, Thomas Madden, Peter Scherrer, David Tirrell, Phalgun Joshi, Jung Soo Kim
-
Publication number: 20060008909Abstract: The present invention includes novel liposomes comprising dihydrosphingomyelin. The invention also includes compositions comprising these liposomes and a therapeutic agent, in addition to methods and kits for delivering a therapeutic agent or treating a disease, e.g., a cancer, using these compositions.Type: ApplicationFiled: May 16, 2005Publication date: January 12, 2006Applicant: Inex Pharmaceuticals CorporationInventors: Pieter Cullis, Thomas Madden, Michael Hope, Steven Ansell, Barbara Mui, Sean Semple, Norbert Maurer
-
Patent number: 6858224Abstract: Particle aggregation of lipid:nucleic acid complex particles is prevented by incorporating a non-cationic lipid into lipid:nucleic acid complex particles containing a cationic lipid and a nucleic acid polymer. The non-cationic lipid is a polyethylene glycol-based polymer.Type: GrantFiled: June 5, 2001Date of Patent: February 22, 2005Assignee: Inex Pharmaceuticals CorporationInventors: Jeffrey Wheeler, Marcel B. Bally, Yuan-Peng Zhang, Dorothy L. Reimer, Michael Hope
-
Patent number: 6858225Abstract: Methods for the preparation of a lipid-nucleic acid composition are provided. According to the methods, a mixture of lipids containing a protonatable or deprotonatable lipid, for example an amino lipid and a lipid such as a PEG- or Polyamide oligomer-modified lipid is combined with a buffered aqueous solution of a charged therapeutic agent, for example polyanionic nucleic acids, to produce particles in which the therapeutic agent is encapsulated in a lipid vesicle. Surface charges on the lipid particles are at least partially neutralized to provide surface-neutralized lipid-encapsulated compositions of the therapeutic agents. The method permits the preparation of compositions with high ratios of therapeutic agent to lipid and with encapsulation efficiencies in excess of 50%.Type: GrantFiled: June 29, 2001Date of Patent: February 22, 2005Assignee: Inex Pharmaceuticals CorporationInventors: Sean C. Semple, Sandra K. Klimuk, Troy Harasym, Michael J. Hope, Steven M. Ansell, Pieter Cullis, Peter Scherrer, Dan Debeyer
-
Patent number: 6841538Abstract: The present invention relates to methods for increasing the efficiency of transformation of cycling cells, the methods comprising synchronizing cells at a first stage of the cell cycle, and transforming the cells at a second stage of the cell cycle within about one cell cycle of the first stage with a genetically engineered nucleic acid that encodes a desired gene product. The invention further relates to cancer therapy and, in particular, to methods of efficiently transforming cancer cells with nucleic acids that encode gene products that inhibit the growth of cancer cells.Type: GrantFiled: April 21, 1999Date of Patent: January 11, 2005Assignees: Inex Pharmaceuticals Corporation, British Columbia Cancer AgencyInventors: Phalgun B. Joshi, Ralph E. Durand, Roger W. Graham
-
Publication number: 20040253302Abstract: This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.Type: ApplicationFiled: December 4, 2003Publication date: December 16, 2004Applicants: Board of Regents, The University of Texas System, Inex Pharmaceuticals CorporationInventors: Andreas H. Sarris, Fernando Cabanillas, Patricia M. Logan, Clive T.R. Burge, James H. Goldie, Murray S. Webb
-
Publication number: 20040228909Abstract: This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.Type: ApplicationFiled: February 18, 2004Publication date: November 18, 2004Applicants: Inex Pharmaceuticals Corporation, Board of Regents, The University of Texas SystemInventors: Andreas H. Sarris, Fernando Cabanillas, Patricia M. Logan, Clive T. R. Burge, James H. Goldie, Murray S. Webb
-
Publication number: 20040170678Abstract: This invention relates to liposomal antineoplastic agents (e.g., camptothecin) compositions and methods of using such compositions for treating neoplasia and for inhibiting angiogenesis. The compositions and methods are useful for modulating the plasma circulation half-life of an active agent.Type: ApplicationFiled: February 27, 2004Publication date: September 2, 2004Applicant: Inex Pharmaceuticals CorporationInventors: Thomas D. Madden, Sean C. Semple, Quet F. Ahkong
-
Patent number: 6723338Abstract: This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.Type: GrantFiled: March 31, 2000Date of Patent: April 20, 2004Assignees: Inex Pharmaceuticals Corporation, Board of Regents, The University of Texas SystemInventors: Andreas H. Sarris, Fernando Cabanillas, Patricia M. Logan, Clive T. R. Burge, James H. Goldie, Murray S. Webb
-
Publication number: 20040071768Abstract: This invention provides compositions and methods for treating neoplasias in a mammal. In particular, the invention provides liposome-encapsulated vinca alkaloids, e.g., vinorelbine, and methods of treating a mammal using such compositions.Type: ApplicationFiled: April 3, 2003Publication date: April 15, 2004Applicants: Inex Pharmaceuticals Corporation, The University of Texas, MD Anderson Cancer CenterInventors: Andreas H. Sarris, Fernando Cabanillas, Patricia M. Logan, Clive T. R. Burge, James H. Goldie, Murray S. Webb, Thomas D. Madden, Sean C. Semple, Quet F. Ahkong, Sandra K. Klimuk
-
Publication number: 20040013649Abstract: The invention discloses cancer vaccines comprising lipid-nucleic acid formulations in combination with one or more tumor-associated antigens which are capable of stimulating strong, Th-1 biased cellular immune responses to said tumor-associated antigens in vivo. It is further disclosed the subject cancer vaccines provide therapeutic efficacy in treating tumors in an animal.Type: ApplicationFiled: May 12, 2003Publication date: January 22, 2004Applicant: Inex Pharmaceuticals CorporationInventors: Ying Kee Tam, Sean C. Semple, Sandra K. Klimuk, Ghania Chikh
-
Publication number: 20040009944Abstract: The invention discloses that methylated nucleic acids, particularly methylated oligonucleotides, and more particularly methylated oligonucleotides bearing a methylated cytosine of a CpG dinucleotide motif can be made immunostimulatory in vivo, by encapsulation of the nucleic acid in a lipid particle. It is further disclosed that encapsulated methylated nucleic acids that are ordinarily not immunostimulatory in vivo are as effective or even more effective than their encapsulated unmethylated counterparts. Also disclosed are methods for activating and/or expanding dendritic cell populations in response to antigenic stimulation using the compositions and methods disclosed herein.Type: ApplicationFiled: May 12, 2003Publication date: January 15, 2004Applicant: Inex Pharmaceuticals CorporationInventors: Ying Kee Tam, Sean C. Semple, Sandra K. Klimuk, Ghania Chikh